by University of Barcelona Credit: Journal of Clinical Investigation Insight (2024). DOI: 10.1172/jci.insight.163359. https://insight.jci.org/articles/view/163359Parkinson’s disease is one of the most common diseases affecting the motor and nervous system. It has no treatment yet, and the pathology causes a deterioration of motor skills due to dopaminergic neuronal death, the neurons that synthesize dopamine, which is a brain...
The metabolic product of an anticancer drug demonstrates potential activity in neurons derived from Parkinson’s patients and a synergistic action, together with the original drug, in prostate cancer cellsPeer-Reviewed Publication SPANISH NATIONAL RESEARCH COUNCIL (CSIC) L’Hospitalet de Llobregat, February 8th, 2024. Once they enter the body, drugs, apart from carrying out their therapeutic function, are...
by University Health Network The model emphasizes the important interactions between three biological factors contributing to Parkinson’s: the presence of pathologic α-synuclein in the brain, evidence of neurodegeneration and the presence of gene variants. Credit: University Health NetworkAn international research team led by Krembil Brain Institute Neurologist and Senior Scientist, Dr. Anthony Lang, has proposed a...
by Marina Romero-Ramos, Aarhus University Differential expression of p62/SQSTM1 autophagy marker in the substantia nigra, piriform cortex and amygdala after α-syn PFF injection. Bar graphs with individual points illustrate the total number of p62+ cells in the SN at a 1 and d 6 months p.i. b Representative images of p62/SQSTM1 immunostaining in α-syn PFF animals...
by Justin Jackson , Medical Xpress Pixabay/CC0 Public DomainResearchers at the Scripps Research Institute, Florida, have developed a new method to counteract α-synuclein protein levels by targeting the mRNA that forms them. The strategy unlocks many research doors with potential therapeutic approaches for addressing neurodegenerative diseases. In a paper, “Decreasing the intrinsically disordered protein α-synuclein...
by University of Southern California Credit: Unsplash/CC0 Public DomainA previously unidentified genetic mutation in a small protein provides significant protection against Parkinson’s disease and offers a new direction for exploring potential treatments, according to a new USC Leonard Davis School of Gerontology study. The variant, located in a mitochondrial microprotein dubbed SHLP2, was found to be...
by University of California, Los Angeles Credit: Pixabay/CC0 Public Domain As Parkinson’s disease diagnoses continue to rise in the U.S., limited patient access to movement disorder specialists means the job of delivering the often-devastating, life-changing news falls on primary care physicians or community neurologists who may not have the necessary expertise for this sensitive task. A...
CONN HASTINGS EXCLUSIVE, NEUROLOGY, REHAB Charco Neurotech, a medtech company based in the United Kingdom, has developed CUE1, a non-invasive wearable that is intended to assist those with Parkinson’s disease to manage their motor symptoms. The device is typically affixed to the sternum, and provides vibratory action in a focused region of the body. The...
Reviewed by Lily Ramsey, LLM In a small study, researchers at the National Institutes of Health have found that positron emission tomography (PET) scans of the heart may identify people who will go on to develop Parkinson’s disease or Lewy body dementia among those at-risk for these diseases. The findings, published in the Journal of...
DURHAM, N.C. – Nanoplastics interact with a particular protein that is naturally found in the brain, creating changes linked to Parkinson’s disease and some types of dementia. In a Duke-led study appearing Nov. 17 in Science Advances, the researchers report that the findings create a foundation for a new area of investigation, fueled by the...
